HANC Newsletter  |  April 2021

Land, Labor, and Justice Acknowledgements

We acknowledge the land we occupy today as the traditional home of the Duwamish, Tulalip, Muckleshoot, and Suquamish tribal nations, the original caretakers of this land who are still here. Without them we would not have access to this working, teaching, and learning environment. We commit to conducting ourselves with dignity and treating this land and all the life it sustains with respect. We ask you to join us in this commitment, wherever you may reside. We also acknowledge exploited labor and ongoing struggle​s for justice on this land. We reflect on the ancestors of our various peoples, nations, tribes, and families; ancestors whose struggles, pain, power, privilege, and strivings we hold in our very bodies.

HANC offices are located at Fred Hutch campus in Seattle, WA.
Recently the pandemic has spotlighted anti-Asian hate crimes and vicious attacks in the news. While these events are saddening and troubling, it’s important to pause and reflect that such aggressive and violent anti-Asian behaviors are not new. The history of ugly and racist behavior against Asians and Asian Americans dates back to the 1800s with the arrival of labor migrants from China to the United States, explicitly brought in to exploit their labor as indentured servants in the aftermath of the emancipation of African slaves. From the 1800s on, Asians and Asian Americans have been relentlessly stereotyped and vilified.

Statistics from the organization Stop AAPI Hate show nearly 3,800 firsthand reports of violence, discrimination, and harassment against Asian Americans since March of last year, including more than 500 incidents in just the first two months of 2021. Many of the incidents were specifically targeted at Asian-American women.

HANC stands in solidarity with our Asian-American staff, colleagues, and community members. We condemn the violence, on-going harassment, and anti-Asian hatred you face. We recognize the systems of oppression and supremacy that are deeply rooted in structural racism. As we acknowledge your grief and pain and we offer our support in ways that you ask for and that are meaningful.

Racism, misogyny, and xenophobia must not be tolerated. HANC calls on all of us to collectively support our diverse global communities and speak up and act against hate. If you see something, say something.

Here are some resources:
Learn about Hollaback bystander intervention to stop anti-Asian American and xenophobic harassment.

As Amanda Gorman so eloquently stated in her inaugural poem “The Hill We Climb”:

We will not be turned around
or interrupted by intimidation
because we know our inaction and inertia
will be the inheritance of the next generation.
For there is always light,
if only we’re brave enough to see it,
if only we’re brave enough to be it.

Welcome to the new HANC website!

The HANC team is excited to launch the newly redesigned Office of HIV/AIDS Network Coordination (HANC) website. Located at the same address, www.hanc.info, the new HANC website is crafted to be easier to navigate, mobile-friendly, and modernized in design.

Our content is now organized into two main areas: Coordination Areas and Resources. With our Coordination Areas section, we want to give a look into who HANC is as an organization, who we work with, and what we do. With our Resources section, we want to showcase the cross-network resources, guidelines, SOPs, and trainings available to you through HANC.

HANC works with the HIV/AIDS clinical trials networks to create a more integrated and collaborative research structure, and we hope these updates will help streamline work with our partners and support the fulfillment of our mission. Minor changes to the HANC logo and color palette were also made as part of the website redesign while still retaining HANC's core color and brand identity. The new website and logo were developed by the Fred Hutch Communications and Marketing team based in Seattle, WA.
Join us in recognizing the following HIV/AIDS Awareness Days this month:

April 10: National Youth HIV/AIDS Awareness Day

NYHAAD educates the public about the impact of HIV/AIDS on youth and highlights the work youth do to strengthen the fight against the HIV/AIDS epidemic.

April 18: National Transgender HIV Testing Day

NTHTD recognizes the importance of routine HIV testing, status awareness and continued focus on HIV prevention and treatment efforts among transgender and gender non-binary people.

Romidepsin Doesn’t Activate HIV-1 Expression in People Living with HIV on ART (A5315)

This exploratory study sought to determine whether romidepsin could awaken latent (‘sleeping’) HIV from its reservoir as part of an HIV cure “kick and kill strategy.” Romidepsin is a histone deacetylase inhibitor drug used to treat cutaneous T cell lymphoma.

In A5315, a randomized, double-blind, placebo-controlled study, investigators evaluated single doses of romidepsin at different amounts for three Cohorts. There were 43 participants with suppressed viral loads on ART that enrolled to prove this approach was safe. Sixteen participants were then enrolled in a final Cohort to receive romidepsin or placebo. Specialized techniques were used to look for HIV in different ways to see if the romidepsin worked.

All romidepsin doses were found to be safe and well-tolerated. However, there were no significant increases in HIV levels (meaning it did not activate sleeping HIV), and romidepsin did not appear to reawaken dormant virus from the reservoir at the doses studied, despite evidence that romidepsin had the expected effect on human cells.

Because studies of histone deacetylase (HDAC) inhibitors as single latency reversal agents, including this study, have failed to show a reduction in the inducible HIV-1 reservoir, other approaches will be needed to achieve a cure for HIV infection.

Bottom line: HDAC inhibitors like romidepsin will not get us closer to finding a way to eliminate the HIV in people. Negative studies like this help scientists move on to more promising approaches.

McMahon, D. K., Zheng, L., Cyktor, J. C., Aga, E., Macatangay, B. J., Godfrey, C., Para, M., Mitsuyasu, R. T., Hesselgesser, J., Dragavon, J., Dobrowolski, C., Karn, J., Acosta, E. P., Gandhi, R. T., Mellors, J. W., & ACTG A5315 Team (2020). A phase I/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 expression (A5315). The Journal of infectious diseases, jiaa777. Advance online publication. https://doi.org/10.1093/infdis/jiaa777

Lower Quality of Life and Lower Adherence Predict Early Virological Failure (A5273/9)

Lower health-related quality of life and lower adherence have been found to be independent predictors of virologic failure among people starting ART in U.S. clinical trials. A5273 evaluated whether quality of life and self-reported adherence could predict early second-line antiretroviral virological failure in less resource-rich countries.

A5273 evaluated two second-line ART regimens among individuals from 15 sites in nine low-middle income countries: Brazil, India, Kenya, Malawi, Peru, South Africa, Tanzania, Thailand, and Zimbabwe. The study defined early virological failure as confirmed HIV-1 RNA viral load higher than 400 copies/mL after 24 weeks of second-line ART. Participants completed the quality of life questionnaire (ACTG SF-21), which has eight domains: General Health Perceptions, Physical Functioning, Role Functioning, Social Functioning, Cognitive Functioning, Pain, Mental Health, and Energy/Fatigue.

Of 500 individuals (51% women, median age 39 years) included in this study, 79% and 75% self-reported complete adherence (no missing doses in the past month) at 4 and 24 weeks after starting second-line ART, respectively. Early virological failure was experienced by 7% and was more common among those who self-reported incomplete adherence. Participants with low quality of life had higher rates of early virological failure.

A5273 verified that lower quality of life adds to self-reported incomplete adherence in predicting early virological failure. These findings indicate that quality of life and adherence assessments after second-line ART initiation could be implemented as real-time measurements to identify individuals at higher risk of subsequent virological failure in low-middle income countries. These individuals may benefit from interventions to improve quality of life, such as social self-value empowerment and yoga, or to optimize adherence, such as text-message reminders.

Bottom line: No matter where you live or how you feel about yourself, your quality of life influences your success or failure in taking medicines to treat HIV.

Torres, T. S., Harrison, L. J., La Rosa, A. M., Zheng, L., Cardoso, S. W., Ulaya, G., Akoojee, N., Kadam, D., Collier, A. C., Hughes, M. D., & for AIDS Clinical Trials Group (ACTG) A5273 Study Group (2021). Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings . AIDS care, 1–10. Advance online publication. https://doi.org/10.1080/09540121.2021.1874275

Evaluating Physical Function Impairment and Frailty in Middle-Aged People Living with HIV (A5361s/2)

As the lifespan of people living with HIV increases, so too do the number of people aging with HIV (nearly half of people living with HIV in the United States are now at least 50 years old). Compared to people without HIV, physical function impairment and frailty are more common and occur at an earlier age in people living with HIV; both have been associated with increased risk of falls, hospitalizations, and death. This paper describes physical function impairment and frailty in middle-aged people living with HIV on stable ART when they enrolled in A5361S (PREPARE), a substudy of REPRIEVE.

A5361S evaluated 266 people living with HIV in the United States, nearly all in their 40s or 50s (81% male, 47% White, 45% Black, 18% Latinx). Many had high body mass index (BMI) and levels of physical activity were low. The investigators found that while overt frailty was uncommon (6%), physical function impairments and pre-frailty were present in nearly half of participants. Physical function impairments appeared mostly in power (the ability to rise from a chair) or strength (grip), important manifestations of skeletal muscle function.

These findings suggest that the time it takes you to stand up from a chair may be a useful screening tool in this relatively young population to detect subtle changes in physical function earlier in age. Additionally, greater BMI, physical inactivity, smoking, and hypertension were associated with physical function impairments. These are important modifiable factors to help target interventions to potentially delay or reduce physical function impairments. The team is continuing to assess physical function yearly to understand any effects of statins over time.

Bottom line: In this relatively younger population with HIV, changes in healthy physical function appeared earlier. Need to learn more about why this happens and the best ways to combat it.

Umbleja, T., Brown, T. T., Overton, E. T., Ribaudo, H. J., Schrack, J. A., Fitch, K. V., Douglas, P. S., Grinspoon, S. K., Henn, S., Arduino, R. C., Rodriguez, B., Benson, C. A., & Erlandson, K. M. (2020). Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE. The Journal of infectious diseases, 222(Suppl 1), S52–S62. https://doi.org/10.1093/infdis/jiaa249
HPTN 091 is now open to accrual. The study will enroll about 310 transgender women (TGW), ages 18 or older, not living with HIV. The vanguard feasibility and acceptability study will assess a multi-component strategy providing HIV prevention services, gender-affirming hormone therapy, and peer health navigation to improve PrEP uptake and adherence. Transgender women bear a disproportionate burden of HIV infection globally, and gender-affirming hormone therapy is an unmet need and community priority for TGW. An accepted and feasible intervention that delivers HIV prevention services with hormonal therapy could significantly impact the HIV epidemic among TGW. Learn more about the study at https://www.iamstudy.org/.
Photo: Courtesy Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Photo: Courtesy McGovern Medical School at UTHealth, Office of Communications

HVTN Responds – Denouncement of Anti-Asian Violence and Hate

The HVTN put out a statement denouncing anti-Asian violence and hate in the wake of recent murders in Atlanta and the noted rise in violence towards Asian communities in response to COVID-19 conspiracy theories. You can read the statement here.

AMP Studies Manuscript Documents Initial Efficacy Results of Proof-of-Concept Trials

The primary manuscript detailing the efficacy results from the global monoclonal antibody studies for HIV prevention was published. The study antibody (VRC01) was found to be very effective at preventing someone from getting strains of HIV that are sensitive to the antibody, but not so effective against strains of HIV that are resistant to the antibody. These proof-of-concept studies support the path forward looking at combinations of antibodies to prevent HIV. You can access the published manuscript here.

HVTN 702 Manuscript in New England Journal of Medicine

Professor Glenda Gray and colleagues led the development of a manuscript focused on the efficacy results of HVTN 702 which was published in the New England Journal of Medicine. You can access the published manuscript here.

HVTN RAMP Scholar Program

This year we accepted 7 scholars for 2021-2022 RAMP Cohort 11. This program is focused on African American/Black and Latinx medical students interested in HIV vaccine research. The HIV Vaccine Trials Network, in collaboration with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, is investing in a young generation of HIV prevention researchers by providing African-American and Latinx medical students with opportunities to conduct independent research while receiving mentoring, project and salary funding, training, and professional development opportunities. Scholars will be working on their projects remotely on 1 long term project and 6 short term projects. 

Long-term Project (9-12 months):
Scholar: India Perez Urbano – University of California San Francisco School of Medicine in San Francisco
Mentor: Dr. Annah Pitsi, Sesthaba Research Center - Soshanguve
Project Title: Patterns of daily pre-exposure HIV prophylaxis use, and barriers and facilitators to its access and use in men who have sex with men and in transgender men and transgender women

Short-term Projects (8-10 weeks):
Scholar: Samuel Owusu, Morehouse School of Medicine 
Mentor: Dr. Katanekwa Njekwa, Lusaka-Matero, Zambia 
Project Title: Clinical profile of COVID-19 in people living with HIV (PLHIV) in Lusaka – A retrospective observational study.

Scholar: Jasmine Robinson, Case Western Reserve University School of Medicine 
Mentor: Dr. Portia Hunidzarira, Harare- Seke South 
Project Title: Mobile health (mHealth) interventions for improving HIV prevention knowledge and clinical research literacy among youth communities in Zimbabwe.

Scholar: Ruth St. Fort, Wright State University Boonshoft School of Medicine
Mentor: Dr. Portia Hunidzarira, Harare- Seke South
Project Title: Mobile health (mHealth) interventions for improving HIV prevention knowledge and clinical research literacy among youth communities in Zimbabwe.

Scholar: Lily Bonadonna, Wayne State University School of Medicine
Mentors: Dr. Magda Sobieszczyk and Dr. Jason Zucker, New York Physicians and Surgeons 
Project Title: Stick2PrEP 3.0 – Understanding Engagement in PrEP Care Among Individuals Receiving Sexual Health Services Before, During, and After the COVID-19 Pandemic

Scholar: Norman Archer, University of California, San Francisco
Mentors: Dr. Magda Sobieszczyk and Dr. Jason Zucker, New York Physicians and Surgeons 
Project Title: Stick2PrEP 3.0 – Understanding Engagement in PrEP Care Among Individuals Receiving Sexual Health Services Before, During, and After the COVID-19 Pandemic

Scholar: Eshiemomoh Osilama, Geisinger Commonwealth School of Medicine 
Mentors: Dr. Magda Sobieszczyk and Dr. Jason Zucker, New York Physicians and Surgeons 
Project Title: Get2PrEP3.0: An Initiative to Reduce Missed Opportunities for the Provision of HIV Prevention Services for Patients Testing Positive for STIs

IMPAACT 2010 Primary Results Released

IMPAACT is proud to announce the presentation of important findings from IMPAACT 2010 at CROI 2021. The Network congratulates the protocol team and study sites for completion of this study and presentation of findings of great importance to the health of women living with HIV and their babies. Learn More.


The IMPAACT P1093 Team is delighted to announce that the European Commission has granted Marketing Authorisation (EMA) approval for the dolutegravir (DTG) 5mg dispersible tablets for children living with HIV in Europe. This decision follows the U.S. Food and Drug Administration approval for this pediatric formulation in June 2020.  Read More.
MTN announced the results of a phase I clinical trial of a 90-dapivirine vaginal ring at the virtual meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) in March. The study, known as MTN-036/IPM 047, evaluated two formulations of the ring designed to slowly release the antiretroviral drug dapivirine in the vagina over the course of 90 days. One formulation contained 100 mg of dapivirine and the other contained 200 mg.

MTN-036/IPM 047 was designed to assess the safety and pharmacokinetics of the 100 mg and 200 mg 90-day rings, compared to the monthly dapivirine ring, which contains 25 mg of active drug. Both formulations were well-tolerated and delivered targeted levels of drug throughout the three months of use, results that would suggest they may have the potential to provide long-acting and sustained HIV protection. The study enrolled 49 HIV-negative individuals at two MTN-affiliated clinical research sites in the United States: the University of Alabama at Birmingham, and Bridge HIV, affiliated with both the SFDPH and the University of California, San Francisco.

COVID Vaccine Matters

Dr. Larry Corey and Dr. Chris Beyrer of the COVID-19 Prevention Network, and colleagues have penned a series of blogs on the Johns Hopkins Coronavirus Resource Center, which can be found here. The latest entry includes commentary on the vaccines, transmission and masks, and the Johnson & Johnson (Janssen) vaccine. 

GPP at Pandemic Speed - Participatory Practice in the Age of COVID-19

AVAC launched Essential Principles & Practices for GPP Compliance: Engaging stakeholders in biomedical research during the era of COVID-19, a new tool to help guide stakeholder engagement in COVID-19 research. Built from the Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP), this new document responds to needs expressed by both researchers and advocates as the world watched COVID-19 research progress with unprecedented speed and urgency.

COVID-19 Toolkits 

The CDC released a new toolkit to assist community-based organizations in educating communities about COVID-19. You can access the toolkit here.

AdCouncil also released a series of toolkits for Black, Hispanic, Faith, and public health communities. You can access the toolkits here.

The Conversation: Between Us, About Us 

Kaiser Family Foundation and the Black Coalition Against COVID-19 launched a new campaign aimed at providing Black communities with credible information about COVID-19 vaccines. In it, Black doctors, nurses, and researchers dispel misinformation and provide facts in 50 FAQ videos. Learn more about the campaign and view the videos here

Community Engagement Materials Menu

updated March 10, 2021
Access all of the CoVPN Community Engagement materials that have been created and share with your friends, colleagues, and communities via a secure Dropbox here (Password: CoVPNTria!$).

HANC COVID-19 Resources

updated March 25, 2021
The HANC COVID-19 Resources page focuses on information about the COVID-19 pandemic and its intersection with the HIV pandemic. Resources are available for community members, people living with HIV, behavioral and mental health researchers, and more. Find it on the HANC website here.

HANC Program Updates

Behavioral and Social Sciences

Greg Davis, HANC Project Manager

The Behavioral Science Consultative Group (BSCG) recently began discussing holding a face-to-face meeting in Q4 of 2021 provided that it is safe to travel and meet. The BSCG would like to congratulate BSCG Co-chair, Dr. Jane Simoni, for being elected to Chair the newly formed ACTG Behavioral Science Subcommittee. 

The Youth Prevention Research Working Group (YPRWG) is finalizing the site survey for the newly funded Network research sites. The survey will assess site knowledge and familiarity with adolescent research. The YPRWG is in the early stages of planning a spring webinar. More details will be available soon.

The COVID-19 CAB Coalition has started creating short videos from COVID-19 Community Advisory Board (CAB) members. The videos will highlight how the community has provided input for COVID-19 trials. The videos will be shared on the HANC website and on social media.

Community Partners

Russell Campbell, HANC Deputy Director

Community Partners has selected Morénike Giwa Onaiwu (US)  and Mighty Ernest Mosimanegape Moseki (Outside US) as the nominees to be considered to serve as the CP Strategic Working Group (SWG) representatives and are awaiting approval from NIAID. SWG representatives serve to provide a direct link between Community Partners and Network leadership. SWG representatives bring a cross-Network community perspective into leadership discussions. 

Community Partners are delighted to have two new representatives from the HPTN. Please join us in welcoming Pearson Mmodzi and Elizabeth Magada!

The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) National Community Advisory Board, Youth Experts and Advocates for Health (ATN-YEAH), Office of HIV/AIDS Network Coordination (HANC), and Community Partners invite you to join Bridging the Gap: Transition from Youth to Adult HIV Care as part of National Youth HIV/AIDS Awareness Day on April 9, 2021. Register here.

Cross-Network Coordination

Milan Vu, HANC Project Manager

The Cross-Network Communications Working Group (CWG) discussed successes and challenges around coverage of the CROI 2021 conference. Access to virtual CROI materials was previously restricted for up to six months after the conference. However, in response to community requests, full and free access to all virtual CROI 2021 recordings will be posted on the CROI website on April 15, 2021 . The CWG also discussed network social media best practices and utilization of various social platforms.

The Cross-Network Site Coordinators Working Group (SCWG) held a joint meeting with DAIDS OCSO Monitoring Operations Branch (MOB) to discuss site challenges and concerns related to remote source document verification (rSDV).

The data management centers (DMCs), in collaboration with DAIDS OPCRO, are developing a training to help sites, laboratories, and other network stakeholders come into compliance with the DAIDS Electronic Information Systems (EIS) Policy. Released in August 2020, the DAIDS EIS Policy describes requirements for electronic systems used in the conduct of NIAID DAIDS Network trials. Implementation of the policy was rolled out in two phases, where Phase 2 groups which include but are not limited to sites, labs, and network leadership and operations centers are expected to comply with the policy by December 1, 2021. Look out for more details about the EIS policy training in May.

DAIDS recently issued several updates to policies impacting clinical research procedures. The policies affected include DAIDS Storage and Retention of Clinical Records Policy; DAIDS Good Documentation Policy (GDP); DAIDS Clinical Research Policy Collection of Financial Disclosure by Clinical Investigators Conducting DAIDS-sponsored IND Trials; and the Enrolling Children (including Adolescents) in Clinical Research Policy. The IMPAACT website has captured a summary of these policies and associated changes.

Laboratory Coordination

Tyler Brown, HANC Project Manager

A new English version of the Good Clinical Laboratory Practice (GCLP) training is now available on the DAIDS Learning Portal. GCLP training, which is now based on GCLP Standards Version 4.1, is intended for staff at laboratories participating in DAIDS-supported and/or sponsored clinical trials. GCLP Standards Version 4.1 was released in February but is not yet effective until August 15 of this year.

The Laboratory Technologists Committee (LTC) met twice in March to discuss laboratory updates to protocol A5401 and new Protocol LT assignments. The group also continued conducting training on protocol participation and Lab Processing Chart preparation.

The Lab Focus Group (LFG) met with the DAIDS Clinical Laboratory Oversight Team (DCLOT) in March to discuss GCLP training, lab supply shortages and the creation of risk mitigation plans for lab quality assurance contract interruptions. Separately the LFG held two ad hoc calls in March.

The Legacy Project

Brian Minalga and Pedro Goicochea, HANC Community Engagement Officers

March 18: On behalf of the Legacy Project, Russell participated and facilitated virtually along with Drs. Lance Okeke and Kenric Ware in a pilot session using the HPR curriculum as part of design consultation groups at South University to receive input from key stakeholders, to develop creative, locally informed initiatives to disseminate information on HIV prevention on HBCU campuses, and by proxy the broader community around HBCUs.

March 19: In observance of National Native HIV/AIDS Awareness Day, the Legacy Project in coordination with the American Indian/Alaska Native working group presented the webinar “Two-Spirit Health Research: Collecting Data in a Culturally Affirming Way”, featuring Harlan Pruden, Jessy Dame and Tyler Adamson.  The webinar covered the impact that colonization had on the cultures of the original nations in the Americas and how western science needs to reconsider its perspective on sex and gender and be more respectful of the cosmovision of these cultures.  Around 33 people attended. 

Conference Report-Back
  • March 23: Brian Minalga represented the Legacy Project during a session focused on molecular HIV surveillance (MHS) at the 2021 AIDS Watch Conference with over 60 participants. Brian is also providing technical assistance to Public Health - Seattle & King County to promote meaningful collaboration with underrepresented populations in local MHS efforts.
  • March 30: Clare Collins, Dazon Dixon Diallo, Brian Minalga, Morénike Giwa Onaiwu, and Rhonda White presented on behalf of the Women's HIV Research Collaborative, "PrEP's Getting a Makeover: Shots, Rings, and Other Splendid Things" at the NMAC Biomedical HIV Prevention Summit. About 160 people attended.
  • March 30: Russell Campbell, Dr. Allysha Maragh-Bass and Dr. Darrell Wheeler presented on behalf of the New Investigators Working Group, “Mentoring Researchers and Care Providers to Address Disparities” at the NMAC Biomedical HIV Prevention Summit. Around 50 people attended.
  • March 31: Pedro Goicochea and Dr. Michele Andrasik presented on behalf of the Legacy Project Working Group, “Participation of Racial/Ethnic Minorities in Clinical Research” at the NMAC Biomedical HIV Prevention Summit. Around 35 people attended. 
April 18: Legacy recognizes National Transgender HIV Testing Day

Upcoming Webinars

Community Update on Current and Future COVID-19 Vaccine Trials

April 6, 2021 at 12:00pm PT / 3:00pm ET
Treatment Action Group (TAG), in partnership with the CoVPN, is hosting a webinar for community advocates to receive a status update on current and future COVID-19 vaccine trials and answer questions related to safety and efficacy data. Learn more about this event and register here

Bridging the Gap: Transition From Youth to Adult HIV Care

April 9, 2021 at 10:00am PT / 1:00pm ET
The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) National Community Advisory Board, Youth Experts and Advocates for Health (ATN-YEAH), HANC, and Community Partners invite you to join Bridging the Gap: Transition from Youth to Adult HIV Care as part of National Youth HIV/AIDS Awareness Day. Members of the ATN-YEAH will participate in a moderated discussion to discuss barriers and facilitators at the individual, clinical, and structural levels that can impact the transition from youth to adult HIV care. Register here.

Faith In Action: COVID Vaccines Faith Leaders Making Informed Decisions 

April 13, 2021 at 9:00am PT / 12:00pm ET
DMV Faith in Action is hosting a webinar to empower faith and community leaders to add to their leadership toolbox, listen to experts, network with other leaders and have an opportunity to build their capacity to comprehensively address health and wellness with their congregations and surrounding neighborhoods. Learn more about this event and register here

Research Priorities & Community Engagement

April 28, 2021 at 10:00am PT / 1:00pm ET
On behalf of the Office of HIV/AIDS Network Coordination and Community Partners, you are invited to participate in a webinar featuring the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network. The IMPAACT Network Leadership will present their research priorities and goals for the next seven years and highlight how community will be engaged as part of their priorities. This is an opportunity for community to engage and ask questions.  Register here.


Good Clinical Laboratory Practice (GCLP v4.1) Training Launches

The updated English version of the "Good Clinical Laboratory Practice (GCLP v4.1)” training is now available on the DAIDS Learning portal. The training comprises of 10 modules that cover GCLP topics. The training is intended for staff at laboratories that are participating in DAIDS-supported and/or sponsored clinical trials to give participants an introduction to GCLP and their relationship to clinical research. Click here to visit the course page and get started.

The DLP is available to site staff and affiliated groups working with the Division of AIDS. If you do not already have an account, click on the Log In button at the top right of the screen then the Create New Account button on the right. Fill out the online form and make sure to include your site ID number (a 2-5 digit number created by DAIDS when the grant was awarded). To confirm the ID number, please contact site PI or the site Program Officer.

If you have any questions about the course or materials, please send an email to the DAIDS Support Team Help Desk.

Conferences & Meetings

May 5-7, 2021
May 20-22, 2021
Week of June 14, 2021
Annual ACTG Network Meeting (Virtual)
July 18-21, 2021
11th IAS Conference on HIV Science (Virtual with local partner hub in Berlin, Germany)

Publication Highlights